Alexander Vlahos Wins 5-Year Breakthrough T1D Grant for Islet Transplant Research
Updated
Updated · Newswise · Jul 10
Alexander Vlahos Wins 5-Year Breakthrough T1D Grant for Islet Transplant Research
1 articles · Updated · Newswise · Jul 10
Summary
Breakthrough T1D awarded Alexander Vlahos a five-year grant to advance subcutaneous islet transplantation, backing a project aimed at improving Type 1 diabetes treatment.
Vlahos’ study seeks to overcome key barriers to islet graft survival beneath the skin, where poor blood vessel growth, immune rejection and cellular stress have limited long-term success.
The project combines synthetic biology and tissue engineering by programming transplanted cells to sense stress and actively reshape their local environment, rather than relying only on biomaterials or porous scaffolds.
Type 1 diabetes destroys insulin-producing pancreatic beta cells, leaving patients dependent on lifelong insulin therapy and making more durable islet transplantation a long-sought potential curative approach.
With new drugs aiding transplants, is engineering cells to build their own homes the true key to a T1D cure?
How will this advanced cell therapy succeed with regulators where previous islet transplants have struggled?
Could cells engineered to build their own blood supply pose unforeseen long-term health risks like cancer?
$5 Million Breakthrough T1D Grant Fuels Vlahos Lab’s Synthetic Circuit Cell Therapy Revolution for Diabetes
Overview
Assistant Professor Alexander Vlahos of Georgia Tech has secured a major five-year grant from Breakthrough T1D to advance innovative research in Type 1 Diabetes. His work focuses on novel cell engineering approaches to overcome key hurdles in islet transplantation, aiming to develop smarter therapies for T1D patients. This achievement highlights the urgent need for new solutions in diabetes treatment and reflects the high caliber of talent and innovation within Vlahos's lab, as further demonstrated by team member Jeremy Hannon receiving a prestigious NIH fellowship. Together, these milestones position the group at the forefront of biomedical engineering research.